History of Cencora

A corporate name with an older story: the idea behind Cencora

Cencora is the corporate successor to AmerisourceBergen, the American drug distributor and services company that built itself by combining national wholesale scale with services for manufacturers, specialty pharmacies and health systems.

The decision to adopt the Cencora name in 2023 reflected a longer evolution in the company’s history: the expansion of a large pharmaceutical distribution business into specialty distribution, manufacturer support and other services. That combination of distribution scale and specialized capabilities shaped the company from its 2001 merger origins through the public-company years and into its present form.

This article traces that evolution: how two established wholesalers became AmerisourceBergen in 2001, how the combined firm expanded into specialty channels and commercial services, how the company weathered legal and regulatory storms, and why the corporate rebrand to Cencora mattered beyond a new logo. The history sheds light on an industry that quietly touches nearly every patient who receives prescription medicines in the United States and increasingly around the world.

“To remain central to drug manufacturers and health systems, the company expanded its distribution foundation to include the management of complex patient, supply-chain and commercial needs—hence, Cencora.”

Quick timeline: key milestones in the history of Cencora

A short, keyword-rich overview highlighting major dates in the history of Cencora and its predecessor, AmerisourceBergen.

• August 29, 2001 — AmeriSource Health Corporation and Bergen Brunswig Corporation completed the merger that formed AmerisourceBergen Corporation.
• Late 2000s–2010s — Legal and regulatory scrutiny over controlled-substance distribution intensified.
• July 1, 2011 — Steven H. Collis became president and chief executive officer of AmerisourceBergen.
• 2000s–2010s — Continued expansion into specialty distribution, patient support and commercial services, including selected international work.
• June 2021 — AmerisourceBergen completed its acquisition of a majority of Walgreens Boots Alliance’s Alliance Healthcare businesses, greatly expanding its international reach.
• August 30, 2023 — AmerisourceBergen Corporation changed its corporate name to Cencora, Inc., and its NYSE ticker changed from “ABC” to “COR.”

Origins and founding: two wholesalers become one

The immediate corporate ancestor of Cencora dates to August 29, 2001, when the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation was completed, forming AmerisourceBergen Corporation. Both companies were long-established players in the drug distribution business: each ran regional distribution networks, served retail pharmacies, hospitals and long-term care facilities, and had developed relationships with drug manufacturers.

The merger responded to clear market pressure. As drug manufacturers consolidated and retailers scaled national operations, distribution economics favored larger partners that could provide consistent national service, tight inventory control and lower per-unit costs. By combining AmeriSource’s and Bergen Brunswig’s networks, the new company aimed to offer national reach and greater purchasing and operating scale.

That merging-of-scale idea defined the early AmerisourceBergen: logistics, operating efficiency and the ability to move large volumes under tight margins. The company took on contracts with national drug chains and hospital systems, and because distribution is a volume business, growth came largely from gaining share at national scale rather than from radical product innovation.

Early development: moving from boxes to services

After the 2001 merger the firm operated principally as a wholesale distributor: warehouses, fleet operations, inventory management and the choreography of daily deliveries to thousands of customers. Those capabilities were essential, but they left margins thin and growth linked to volume and efficiency gains.

Two dynamics encouraged the company to broaden its capabilities. First, new drugs—particularly biotech and specialty medicines—could be expensive, require cold-chain logistics, and need specialized handling and patient support programs. Second, manufacturers increasingly sought services beyond freight, including market-access assistance, patient support, specialty-medicine hub services and commercialization support.

AmerisourceBergen responded by layering services onto its distribution base. It developed specialty distribution capabilities, including controlled-temperature storage and secure handling for high-value products, and built or expanded businesses that provided patient support, reimbursement services and specialty pharmacy relationships.

In essence, the company began to sell expertise as well as throughput. That shift broadened its offerings and changed its relationship with some drug manufacturers from a conventional distribution vendor to a partner providing multiple forms of supply-chain and commercialization support.

Expansion and growth: building a portfolio beyond wholesale

Through the 2000s and 2010s AmerisourceBergen’s expansion followed two tracks: scale in core distribution and deliberate growth into specialty and commercial services.

• Core distribution scale. The firm continued to invest in distribution centers, technology to manage inventory and replenishment, and logistics capabilities that allowed it to serve national pharmacy chains, independent pharmacies, hospitals and clinics. Scale remained the company’s baseline advantage.
• Specialty and services. AmerisourceBergen broadened its business to include specialty pharmacy services, oncology distribution support, and programs that help patients access high-cost medicines. That work required clinical support staff, complex billing expertise, and closer contractual ties with drug manufacturers.

Those two tracks were complementary. Distribution infrastructure gave the company operational strength, while the services businesses broadened its capabilities and customer relationships. The combination strengthened AmerisourceBergen’s market position: when manufacturers needed complex commercial solutions, they could turn to a firm that could both ship products and support the administration and financing of modern therapies.

Major milestones that reshaped the company

AmerisourceBergen’s history includes a series of strategic moves that cumulatively remade the firm. Among the most consequential were:

• Integration after the 2001 merger. The early decade after the merger involved consolidating warehouses, harmonizing IT and combining sales forces. Those integration choices determined whether the company would realize the cost and service benefits that justified the merger.
• Pivot toward specialty distribution and manufacturer services. Building specialty channels—cold chain, secure handling and patient support—broadened the company’s capabilities and its relationships with pharmaceutical manufacturers whose therapies demanded more than conventional wholesale delivery.
• International expansion. AmerisourceBergen extended its distribution and commercial services beyond the United States, most notably through its 2021 acquisition of a majority of Alliance Healthcare’s businesses from Walgreens Boots Alliance.
• Escalating legal and regulatory attention to controlled substances. As concerns about opioid misuse and community health grew, wholesalers—including AmerisourceBergen—faced lawsuits and investigations by state, local and federal authorities concerning their controlled-substance distribution practices.

Each milestone mattered because it altered the company’s capabilities, geographic reach or risk profile. Specialty services broadened its relationships with manufacturers; international expansion diversified its operations; and opioid litigation produced substantial settlement obligations and compliance requirements.

Leadership and organizational changes: steering the shift to services

Leadership decisions mattered in how aggressively the company pursued the services strategy. One clear inflection point came on July 1, 2011, when Steven H. Collis succeeded R. David Yost as president and chief executive officer of AmerisourceBergen.

Under Collis the firm emphasized long-term partnerships with manufacturers, investments in specialty distribution and clinical support services, and a customer-facing approach that treated distributors as part of the solution to manufacturers’ commercialization challenges rather than just low-cost transporters.

That executive-level shift aligned incentives across the organization. Operations still needed to be efficient, but sales, clinical services and commercial solutions teams received greater institutional prominence. The result was a company that could present itself to a biotech or specialty drug maker as a broad commercialization and distribution partner.

Acquisitions, spinouts and ownership changes

AmerisourceBergen combined internal investment with acquisitions that added specialty, patient-support, logistics and international capabilities. Its most consequential acquisition of this period was the purchase of a majority of Walgreens Boots Alliance’s Alliance Healthcare businesses, completed in June 2021 for $6.275 billion in cash, subject to adjustments, and 2 million AmerisourceBergen shares.

The Alliance Healthcare transaction expanded AmerisourceBergen’s wholesale and pre-wholesale operations into additional countries and added breadth to its global manufacturer-services platform. Other transactions added specialized teams, distribution assets, technologies and service platforms.

Corporate ownership remained public throughout this period, and the company used capital markets to support investments in acquisitions, automation, distribution infrastructure and service platforms.

Public-company status brought external scrutiny—quarterly reporting and investor pressure for performance—and that pressure influenced decisions about where to allocate capital across distribution and service operations.

Challenges and controversies: opioid litigation and regulatory pressure

Opioid litigation: timeline and outcomes

No history of AmerisourceBergen—now Cencora—can omit the legal and policy challenges arising from opioid distribution. State and local governments, including New York and Washington, brought claims against AmerisourceBergen Drug Corporation alongside other national distributors over their alleged roles in the prescription-opioid crisis.

A nationwide distributor settlement became effective on April 2, 2022. Under its terms, AmerisourceBergen agreed to contribute up to approximately $6.1 billion over 18 years, while the participating distributors accepted injunctive requirements that included a shared clearinghouse for controlled-substance order data. As of March 31, 2026, Cencora reported that 48 of 49 eligible states and political subdivisions representing 99% of the eligible population in those states had joined the settlement.

Separately, on December 29, 2022, the U.S. Department of Justice filed United States v. AmerisourceBergen Corporation et al., No. 2:22-cv-05209, in the U.S. District Court for the Eastern District of Pennsylvania. The civil complaint named AmerisourceBergen Corporation, AmerisourceBergen Drug Corporation and Integrated Commercialization Solutions, LLC and alleged failures to report suspicious controlled-substance orders to the Drug Enforcement Administration. The government sought civil penalties and injunctive relief. The claims are allegations, and Cencora’s filings continued to describe the case as pending in 2026.

These proceedings created substantial settlement obligations and continuing legal costs. The nationwide settlement also imposed monitoring, data-sharing and other injunctive requirements intended to strengthen controls over controlled-substance distribution.

Recent development and the rebrand to Cencora

The most visible recent turning point was the corporate renaming on August 30, 2023. AmerisourceBergen Corporation changed its legal name to Cencora, Inc., began operating under the Cencora identity and changed its New York Stock Exchange ticker from “ABC” to “COR.”

The rebrand reflected a company with a broader global footprint and a portfolio spanning pharmaceutical distribution, specialty logistics, manufacturer services and patient-support offerings. Cencora presented the new name as a unified identity for businesses connecting manufacturers, providers, pharmacies and patients while continuing to emphasize pharmaceutical distribution as a core operation.

The branding change did not mean that every subsidiary immediately adopted a new legal name. Subsequent SEC filings continued to list entities such as AmerisourceBergen Drug Corporation, AmerisourceBergen Services Corporation and AmerisourceBergen Specialty Group, LLC, even as the group operated publicly under the Cencora brand.

Alongside the new corporate name, the company continued to operate distribution networks and service businesses that had been developed or acquired over the prior two decades. The renaming did not erase the firm’s wholesale roots; rather, it brought a geographically and operationally diverse group of businesses under a shared public identity.

How Cencora works today: business lines and the modern model

In its present form Cencora remains centered on the distribution and commercialization of medicines. Its principal activities can be described at a high level:

• Pharmaceutical distribution. The company operates distribution networks that serve retail pharmacies, health systems and other providers. That business remains critical because reliable, timely delivery of medicines is indispensable to health-care operations.
• Specialty distribution and patient support. Cencora handles complex biologics and specialty therapies that can require temperature control, specialized packaging, patient enrollment and support services.
• Commercial and manufacturer services. The company provides services to drug manufacturers that include market-access support, launch assistance, logistical coordination and data-related offerings. These services complement its pharmaceutical distribution infrastructure.

That mixed model affects how the company allocates capital, hires talent and interacts with regulators. Its investments span distribution capacity, cold-chain infrastructure, technology, manufacturer services and patient-support capabilities. Cencora does not report a separate company-wide measure of service revenue that establishes that services have replaced distribution as its principal source of revenue; its public reporting instead presents services and specialty capabilities as complements to a core pharmaceutical distribution business.

Legacy and significance: what Cencora changed in drug distribution

Cencora’s historical significance is less about a single invention than about a pattern of industry change it both rode and helped create. Three enduring contributions stand out:

• Expansion of bundled manufacturer services. By building patient-support programs, hub services and commercialization teams alongside distribution, the company participated in the industry’s expansion of the distributor’s role beyond conventional wholesale delivery.
• Operational scale as a market-making force. The consolidation of distribution networks into national-scale operations changed procurement and inventory practices across pharmacies and health systems. Large wholesalers like AmerisourceBergen created infrastructure that manufacturers relied on for national distribution.
• Combining logistics with specialized capabilities. Cencora’s expansion shows how large distributors added cold-chain logistics, specialty handling, patient services and manufacturer support as pharmaceutical products and supply chains became more complex.

At the same time, the controversies over controlled substances spotlighted how tightly the pharmaceutical supply chain is connected to public health outcomes. The resulting litigation and settlements placed new attention on monitoring, reporting, data sharing and the responsibilities of manufacturers, distributors and pharmacies.

Conclusion: from national wholesaler to global distribution and services company

Cencora’s story is a business-school lesson in strategic adaptation. Born from a 2001 merger that sought national scale in a low-margin business, the company expanded its specialty distribution, manufacturer services and international operations as pharmaceutical products and supply chains became more complex.

Leadership choices in the 2010s emphasized services alongside distribution; acquisitions and investments broadened the company’s logistics, patient-support and commercial capabilities; and the 2023 rebrand to Cencora publicly acknowledged a more global and unified identity.

Today, the company combines distribution scale with specialty logistics, patient support and commercial services for manufacturers. Its legacy is mixed: it helped make the drug distribution system more centralized and efficient, and it demonstrated how a distributor could add specialized services; it was also tested by controversies that exposed the legal and public-health consequences of controlled-substance distribution. The central theme of its evolution is clear: the company retained distribution as its foundation while adding the capabilities needed to manage increasingly complex pharmaceutical supply chains and commercial programs.